We are thrilled to announce our partnership with Beijing BIOOCUS Biotech Ltd. to bring innovative cell therapy to patients in China. This collaboration brings together Adaptimmune's cutting-edge technology and BIOOCUS's expertise in the development and commercialization of advanced therapeutics, Our lead product candidate, ADP-A2M4, is a novel T-cell therapy targeting MAGE-A4, a common cancer antigen. This therapy has shown promising results in clinical trials for the treatment of multiple solid tumors. Through this partnership, we aim to accelerate the clinical development and regulatory approval of ADP-A2M4 in China, providing much-needed treatment options for patients with these difficult-to-treat cancers
Please feel free to give your inquiry in the form below We will reply you in 24 hours